Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

NCT05168813 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

14237

Enrollment

NETWORK

Sponsor class

Conditions

SARS-CoV-2 Infection
HIV Infections
COVID-19

Interventions

BIOLOGICAL: Moderna mRNA-1273
BIOLOGICAL: Moderna mRNA-1273.222
BIOLOGICAL: Vaccine 3 Dose
BIOLOGICAL: Vaccine 2 Dose

Sponsor

COVID-19 Prevention Network

Collaborators

[object Object]
[object Object]